ICY­MI: 'What could they pos­si­bly buy?' Sanofi's Paul Hud­son talks M&A hes­i­ta­tion at #JPM23

SAN FRAN­CIS­CO — Sanofi CEO Paul Hud­son sees Big Phar­ma be­ing “clear­ly hes­i­tant” to jump on ma­jor M&A deals amid a con­flu­ence of un­cer­tain­ties, from the new­ly passed In­fla­tion Re­duc­tion Act to the loom­ing patent cliff for many of the ma­jor med­i­cines cur­rent­ly on the mar­ket.

Speak­ing to a small group of re­porters on the out­skirts of #JPM23 flanked by his C-suite, Hud­son sug­gest­ed Sanofi shares the hes­i­ta­tion but is not in a rush to act be­cause of the in­ter­nal pipeline that R&D chief John Reed has built up over the past four years, when the French phar­ma gi­ant joined its peers in turn­ing it­self in­to a “sci­ence-led” com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER